Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity‐modulated chemoradiation

Abstract

A risk model based on multiple factors instead of p16 as single marker can define different risk groups to select patients for treatment deintensification in future prospective clinical trials.

No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression

“…In accordance with the literature [11,13,23,[47][48][49][50][51][52] p16 overexpression was the most important positive prognostic factor for outcome in our cohort irrespective of the type of neck treatment.…”

“…The 5 years survival analysis of the entire patient cohort with only advanced tumor stages (UICC stage IV) achieved a respectably good OS of 63 % and DSS of 72 %, which is comparable to one of our previous studies [23] and even slightly superior to the survival estimates reported in the literature [11,24,25] in similar patient cohorts. The high overall regional control rate of 95 % in the PND group was in line with the literature [26][27][28].…”

Oropharyngeal squamous cell carcinoma in the veteran population: Association with traditional carcinogen exposure and poor clinical outcomes

“…The differences in OS and progression‐free survival were stark: HRs for death and relapse or death were 0.29 and 0.33, respectively, for patients in the low‐risk group compared to the high‐risk group . The profound effect of HPV on oropharyngeal SCC outcomes has been confirmed in multiple retrospective single institution and nationwide database analyses . Together, these data have led to increased optimism regarding the future of clinical outcomes for patients with oropharyngeal SCC.…”

Prognostic value of pretreatment 18F‐fluorodeoxyglucose positron emission tomography/CT volume‐based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status

“…p16 is an oncoprotein generated by HPV that is overexpressed in almost all HPV‐positive oropharyngeal SCC specimens and is a surrogate marker of HPV infection . p53 is a tumor suppressor that is overexpressed when p53 missense mutations occur and has a significant impact on survival outcome as a surrogate marker for smoking in oropharyngeal SCC . In our previous study, we suggested that evaluating p16 and p53 status by immunohistochemical staining (IHC), which is simple to carry out in clinical practice, may permit risk‐stratification of oropharyngeal SCC cases …”